EGFR and KRAS mutations, activation of Src kinase, and elevated expression of interleukin-6 (IL-6) are among several molecular aberrations have been identified in lung cancer that often result in the activation of STAT3 [32–34]. The gene discussed is KRAS; the disease is lung carcinoma.